Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Research / Clinical Trials / Study Details

Ustekinumab for Primary Sjogren's Syndrome

Research Question:
What is the safety and effect of the drug, ustekinumab, in patients with Primary Sjogren's Syndrome?

Basic Study Information

Ustekinumab is FDA approved for treatment of Psoriasis, Psoriatic Arthritis, and Crohn's disease, but it has not been previously used in the treatment of Primary Sjogren's Syndrome. Participants will complete 6 study visits over the course of 6 months. Subjects will receive an infusion of ustekinumab at the second visit and an injection of ustekinumab at the next 3 visits. Subjects will have assessments of their health at all visits.

Location: University of Rochester
Study Reference #: 3820

Lead Researcher (Principal Investigator)

Lead Researcher:  Ummara Shah

Study Contact Information

Study Coordinator: Alena Leger
Phone: (585) 275-1634

Additional Study Details

Number of Visits:  6 to 10
Parking:  Reimbursed
Reimbursement:  Yes

Learn More About These Conditions

More information about Sjogren's Syndrome

Return to Search